Benzamide ionizable lipid or salt thereof, nano delivery system and application thereof

By designing the combination of benamide ionizable lipids and auxiliary lipids, stable lipid nanoparticles are formed, which solves the problem of insufficient lipid nanoparticles escape ability in the cell, and improves the delivery efficiency and biological phase of nucleic acid drugs Capacity enables efficient delivery of nucleic acid drugs.

CN118908849AActive Publication Date: 2024-11-08SHANDONG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410943784.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

The existing lipid nanoparticles (LNPs) lack the ability to escape endosomes in cells, resulting in low nucleic acid drug delivery efficiency and insufficient biocompatibility and safety of ionizable lipids, affecting the therapeutic effect of the drug.

Method used

Using benzide ionizable lipids or their salts, by optimizing their structural design, lipid nanoparticles with uniform particle size and stable structure are formed, combining auxiliary lipids and cholesterol, promoting lysosomal escape of nucleic acid molecules and improving transfection efficiency and improve biocompatibility.

Benefits of technology

It realizes efficient nucleic acid molecular encapsulation and endosomal escape, improves transfection efficiency, reduces cytotoxicity, enhances biocompatibility, and improves the delivery system of nucleic acid drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908849A_ABST
    Figure CN118908849A_ABST
Patent Text Reader

Abstract

The invention discloses a benzamide ionizable lipid or salt thereof, a nano delivery system and application thereof, the structural formula of the benzamide ionizable lipid is as shown in formula I: # imgabs0 #, R0 is selected from L-type or D-type amino acid side chain group (R group); r1 to R6 are respectively and independently selected from substituted or unsubstituted C6-C24 alkyl groups; or, a substituted or unsubstituted C6-C24 alkenyl group, a substituted or unsubstituted C6-C24 alkenyl group; or a substituted or unsubstituted C6-C24 alkynyl group, a substituted or unsubstituted C6-C24 alkynyl group; r7 is selected from H and substituted or unsubstituted C1-C10 alkyl groups; m is an integer selected from 1-8; x is selected from O or NH. Nucleic acid molecules can be efficiently encapsulated, and LNP with uniform particle size and stable structure is formed. In addition, the prepared LNP can effectively promote lysosome escape of nucleic acid molecules, and is high in transfection efficiency and good in biocompatibility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a benzamide ionizable lipid or a salt thereof, a nano delivery system and applications thereof. Background Art

[0002] The statements herein merely provide background information related to the present invention and do not necessarily constitute prior art.

[0003] Nucleic acid drugs (including DNA and RNA) are drugs with specific base sequences, among which DNA drugs include plasmids and antisense oligonucleotides, and RNA drugs include messenger RNA (mRNA) and small interfering RNA (siRNA). Since nucleic acid molecules are easily cleared by blood circulation, the key to the therapeutic effect of drugs is to safely and efficiently deliver specific genes into cells.

[0004] At present, lipid nanoparticle (LNP)-mediated nucleic acid drug delivery is one of the most widely used delivery systems. The LNP system is composed of four major lipid classes, mainly including ionizable lipids (or cationic lipids), auxiliary lipids, cholesterol, and PEGylated lipids (PEG-lipids). Among them, ionizable lipids are the key components of the formulation, which are neutral at physiological pH and positively charged at the acidic pH of the endosome to maximize potential toxicity. However, to date, only 1%-2% of the nucleic acid payload can eventually escape from the late endosome to the cytoplasm in the cell through LNP. Therefore, there is still an urgent need to develop ionizable lipids with efficient endosomal escape ability to improve nucleic acid drug delivery in vitro and in vivo.

[0005] Ionizable lipids can be used as multi-component molecules, and each part must be precisely designed to safely and effectively package and deliver nucleic acids. In general, ionizable lipids are composed of three parts: an amino head, a linker, and a hydrophobic tail. The amino head is mainly involved in the process of encapsulating nucleic acids, stabilizing LNPs, interacting with cell membranes, and promoting endosomal escape; the linker connects the head and tail to affect the stability and biodegradability of LNPs; the hydrophobic tail affects lipid fluidity and fusion, thereby affecting the formation and efficacy of LNPs. The modification and optimization of the above three parts of ionizable lipids determine the ionization behavior and surface charge of LNPs, and further affect the stability and toxicity of LNPs. Therefore, on the premise of ensuring that LNPs prepared from ionizable lipids have good endosomal escape ability, it is necessary to develop ionizable lipids with higher biocompatibility and stronger in vivo safety. Summary of the invention

[0006] In view of the shortcomings of the prior art, the object of the present invention is to provide a benzamide ionizable lipid or its salt, a nano delivery system and its application. The benzamide ionizable lipid with a new structure provided by the present invention can efficiently encapsulate nucleic acid molecules to form LNPs with uniform particle size and stable structure. In addition, the prepared LNPs can effectively promote the lysosomal escape of nucleic acid molecules, with high transfection efficiency and good biocompatibility.

[0007] In order to achieve the above object, the present invention is implemented through the following technical solutions:

[0008] In a first aspect, the present invention provides a benzamide ionizable lipid or a salt thereof, the structural formula of which is shown in Formula I:

[0009]

[0010] Wherein, R0 is selected from L-type or D-type amino acid side chain groups (R groups);

[0011] R1-R6 are each independently selected from substituted or unsubstituted C6-C 24 Alkyl; or, substituted or unsubstituted C6-C 24 or, substituted or unsubstituted C6-C 24 Alkynyl;

[0012] R7 is selected from H, substituted or unsubstituted C1-C 10 alkyl;

[0013] m is an integer selected from 1 to 8;

[0014] X is selected from O or NH.

[0015] In some embodiments, the amino acid of the side chain group of R0 is selected from glycine, alanine, proline, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, asparagine, glutamine, lysine, histidine, arginine, aspartic acid or glutamic acid.

[0016] Preferably, the amino acid of the side chain group of R0 is selected from glycine, alanine, proline, valine, leucine, isoleucine, methionine, lysine, histidine or arginine.

[0017] More preferably, the amino acid of the side chain group of R0 is leucine or methionine.

[0018] In some embodiments, R1-R6 are each independently selected from substituted or unsubstituted C6-C 24 alkyl.

[0019] Preferably, R1-R6 are each independently selected from C8-C 14Straight chain alkyl.

[0020] In some embodiments, R7 is H; X is NH; m is 4.

[0021] In some embodiments, the benzamide ionizable lipid is selected from one of the following compounds:

[0022]

[0023]

[0024] In a second aspect, the present invention provides a nano-delivery system, comprising the benzamide ionizable lipid or a salt thereof.

[0025] In some embodiments, the nanodelivery system further comprises one or more of a helper lipid, cholesterol and its derivatives, or a PEG lipid.

[0026] Preferably, the helper lipid is a phospholipid or a derivative thereof.

[0027] Further preferably, the auxiliary lipid is selected from one or more of distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), diethyl pyrocarbonate (DEPC), dilauroylphosphatidylcholine (DLPC), phosphatidylcholine (POPC), egg yolk phosphatidylcholine (EPC), hydrogenated soy phosphatidylcholine (HSPC), sphingomyelin (SM) or dimyristoylphosphatidylcholine (DMPC).

[0028] Preferably, the cholesterol derivative is selected from one or more of sterols and their derivatives, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatine, ursolic acid, α-tocopherol or corticosteroids.

[0029] Preferably, the PEG lipid is selected from one or more of DSPE-PEG, DMG-PEG, DPPE-PEG or DMA-PEG.

[0030] In some embodiments, the nanodelivery system comprises the benzamide ionizable lipid or its salt, auxiliary lipid, cholesterol or its derivative or PEG lipid, wherein the molar ratio of the benzamide ionizable lipid or its salt, auxiliary lipid, cholesterol or its derivative and the PEG lipid is 20-50:20-60:10-40:0.5-10.

[0031] In a third aspect, the present invention provides use of the nano-delivery system in the preparation of nucleic acid drugs.

[0032] In some embodiments, the nucleic acid molecule in the nucleic acid drug is selected from one or more of small interfering RNA (siRNA), messenger RNA (mRNA), MicroRNA (miRNA), circular mRNA, long non-coding RNA (lncRNA), plasmid DNA, mini circle DNA (mcDNA), antisense oligonucleotides (ASOs), small activating RNA (saRNA) or nucleic acid aptamers (Aptamer).

[0033] Preferably, the nucleic acid molecule is small interfering RNA (siRNA), messenger RNA (mRNA) or circular mRNA.

[0034] In some embodiments, in the nucleic acid drug, the mass ratio of the benzamide ionizable lipid or its salt to the nucleic acid molecule is 1-100:1.

[0035] Preferably, the particle size of the nucleic acid drug is 1-1000 nm.

[0036] Preferably, the nucleic acid drug includes a targeting molecule, and the targeting molecule is located in the nucleic acid drug or on the surface of the nucleic acid drug.

[0037] Further preferably, the targeting molecule is selected from proteins, peptides, glycoproteins, lipids, small molecules or nucleic acids, such as antibodies, antibody fragments, low-density lipoprotein (LDL), transferrin, asialoglycoprotein, receptor ligands, sialic acid, aptamers, etc.

[0038] Nucleic acid drugs can be prepared using any method known in the art. These methods include, but are not limited to, liposome extrusion, thin film differentiation, nanoprecipitation, microfluidics, and impinging jet mixing, as well as other methods well known to those of ordinary skill in the art.

[0039] Preferably, the preparation method of the nucleic acid drug comprises: dissolving one or more of the lipid compound, the auxiliary lipid, the cholesterol, and the PEG lipid in ethanol to obtain a lipid mixed ethanol phase; fully dispersing the nucleic acid molecules in a citric acid buffer at pH = 4 to obtain a drug aqueous phase; using microfluidics to quickly mix the lipid mixed ethanol phase and the drug aqueous phase to prepare a solution containing lipid nanoparticles; and then obtaining lipid nanoparticles, i.e., nucleic acid drugs, through dialysis, ultrafiltration and other steps.

[0040] The nucleic acid drug can be used for the prevention and treatment of various diseases in humans and / or animals orally, rectally, intravenously, intramuscularly, intravaginally, intranasally, subcutaneously, intraperitoneally, buccally, or in the form of oral administration, injection or inhalation.

[0041] Preferably, the nucleic acid drug is used for preventing and / or treating cancer, inflammation, fibrotic disease, autoimmune disease, infection, mental disorder, blood disease, chromosomal disease, genetic disease, connective tissue disease, digestive disease, ear, nose and throat disease, endocrine disease, eye disease, reproductive disease, heart disease, kidney disease, lung disease, metabolic disease, oral disease, musculoskeletal disease, neonatal screening, nutritional disease, parasitic disease or skin disease.

[0042] The beneficial effects achieved by one or more embodiments of the present invention are as follows:

[0043] 1. The benzamide ionizable lipid provided by the present invention has good biodegradability with amino acids (such as methionine and leucine) as connecting groups and amide bonds as connecting bonds, and the obtained lipid compounds and their salts have lower cytotoxicity. In addition, the phenyl groups in the lipid compounds can have a II-II stacking effect with the bases in the nucleic acid molecules, thereby improving the interaction between lipid and nucleic acid molecules, and being conducive to achieving efficient compression of nucleic acid molecules.

[0044] 2. The benzamide ionizable lipids provided by the present invention are uncharged under physiological conditions (pH=7.4), but are positively charged under acidic conditions. The lipid nanoparticles are protonated as the pH of the endosomal changes, the lipid compounds are positively charged, and the hydrophobic tails are combined with the negatively charged lipids to form an unstable inverted hexagonal phase, which promotes the fusion of LNP with the endosomal membrane and is conducive to the endosomal escape of nucleic acid molecules.

[0045] 3. The present invention can increase the structural diversity of lipid compounds in existing delivery systems, enrich existing delivery systems of nucleic acid drugs, and facilitate the development and application of nucleic acid drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0047] Figure 1 It is the particle size and PDI of the lipid nanoparticles prepared in Example 3 of the present invention.

[0048] Figure 2 This is the Zeta potential characterization of the lipid nanoparticles prepared in Example 3 of the present invention.

[0049] Figure 3 is the encapsulation efficiency of the lipid nanoparticles prepared in Example 3 of the present invention.

[0050] Figure 4 It is a transmission electron micrograph of the lipid nanoparticles prepared in Example 3 of the present invention.

[0051] Figure 5 This is the result of investigating the transfection efficiency of the lipid nanoparticles prepared in Example 3 of the present invention. DETAILED DESCRIPTION

[0052] It should be noted that the following detailed descriptions are illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0053] Terminology explanation:

[0054] The term "alkyl" refers to a saturated straight or branched hydrocarbon group. In some embodiments, the alkyl group has 6-24 carbons, also referred to as a C6-C24 alkyl. The alkyl group can be straight or branched, and the alkyl group can be substituted by one or more groups selected from halogen, hydroxyl, amino, oxo, alkoxycarbonyl, amide, alkylamido, dialkylamido, nitro, amino, alkylamino, dialkylamino, carboxyl, thio and thioalkyl.

[0055] The term "alkenyl" refers to a straight, cyclic or branched hydrocarbon group containing at least one carbon-carbon double bond. In some embodiments, the alkenyl group has 6-24 carbons, also referred to as C6-C24 alkenyl. The alkenyl group may be substituted by one or more substituents selected from those defined above for the substituted alkyl.

[0056] The term "alkynyl" refers to a straight or branched hydrocarbon group containing at least one carbon-carbon triple bond. In some embodiments, the alkynyl group has 6-24 carbons, also referred to as C6-C24 alkynyl. The alkynyl group may be substituted by one or more substituents selected from those defined above for substituted alkyl.

[0057] "Substitution" refers to that one or more hydrogen atoms in a group are independently replaced by a corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible substitutions without paying too much effort.

[0058] In the context of the present invention, alkyl, alkene and alkyne moieties as defined herein may further comprise one or more heteroatoms, e.g. a carbon in the alkyl, alkene or alkyne chain is replaced by a heteroatom such as selected from nitrogen, oxygen or sulfur.

[0059] The terms "nucleic acid" and "nucleic acid molecule" may be used interchangeably herein. The term refers to polymers of deoxyribonucleotides (DNA), ribonucleotides (RNA) and modified forms thereof, either as individual fragments or as components of larger constructs, linear or branched, single-stranded, double-stranded, triple-stranded or hybrids thereof.

[0060] The structural formulas of compounds L1, L2, L3, L4, M1, M2, M3 and M4 are shown in Table 1.

[0061] Table 1

[0062]

[0063]

[0064] The present invention will be further described below in conjunction with the embodiments.

[0065] Example 1

[0066]

[0067] Synthesis of compound L2

[0068] Synthesis of compound 1: Dissolve N-tert-butyloxycarbonyl-1,2-butanediamine (10mmol), 1-bromodecane (22mmol), and potassium carbonate (20mmol) in acetonitrile (60ml), heat to 80°C, and stir under reflux for 72h. After TLC detection of the reaction, use a rotary evaporator to remove the solvent under reduced pressure. Add 50mL of ethyl acetate, wash with an equal volume of saturated sodium chloride solution 3 times, dry with anhydrous sodium sulfate for 30min, use a rotary evaporator to remove the solvent under reduced pressure, and separate and purify by column chromatography (eluent: methanol: dichloromethane volume ratio = 1:20), and obtain compound 1 with a yield of 74%.

[0069] Synthesis of compound 2: Compound 1 (5 mmol) was dissolved in dichloromethane (30 mL), trifluoroacetic acid (10 mmol) was added, and the reaction was stirred at room temperature for 2 h. After TLC detection of the reaction, the solvent was removed by vacuum distillation using a rotary evaporator. Saturated potassium carbonate solution was added and the pH was adjusted to 7. 50 mL of ethyl acetate was added, and an equal volume of saturated sodium chloride solution was washed 3 times, dried over anhydrous sodium sulfate for 30 min, and the solvent was removed by vacuum distillation using a rotary evaporator to obtain compound 2 with a yield of 95%. 1 H NMR(400MHz,Chloroform-d)δ5.21(d,J=6.4Hz,1H),3.11(d,J=5.7Hz,2H),2.43(q,J= 7.9Hz, 4H), 1.49 (s, 4H), 1.44 (s, 12H), 1.31 (d, J = 7.1Hz, 28H), 0.88 (t, J = 6.7Hz, 6H).

[0070] Synthesis of compound 3: BOC-L-leucine (10 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 20 mmol), and 1-hydroxybenzotriazole (HOBT, 10 mmol) were dissolved in dichloromethane (60 ml), and compound 3 (8 mmol) was added.

[0071] The reaction was stirred at room temperature for 12 h. After TLC detection, the solvent was removed by vacuum distillation using a rotary evaporator. 50 mL of ethyl acetate was added, and the mixture was washed three times with an equal volume of saturated sodium chloride solution, dried over anhydrous sodium sulfate for 30 min, and the solvent was removed by vacuum distillation using a rotary evaporator. The mixture was separated and purified by column chromatography (eluent: methanol: dichloromethane volume ratio = 1:50) to obtain compound 3 with a yield of 67%.

[0072] Synthesis of compound 4: Compound 3 (5 mmol) was dissolved in dichloromethane (30 mL), trifluoroacetic acid (10 mmol) was added, and the reaction was stirred at room temperature for 2 h. After TLC detection of the reaction, the solvent was removed by vacuum distillation using a rotary evaporator. Saturated potassium carbonate solution was added and the pH was adjusted to 7. 50 mL of ethyl acetate was added, and an equal volume of saturated sodium chloride solution was washed 3 times, dried over anhydrous sodium sulfate for 30 min, and the solvent was removed by vacuum distillation using a rotary evaporator to obtain compound 4 with a yield of 90%.

[0073] Synthesis of compound L2: Compound 4 (3.6 mmol) and triethylamine (3.6 mmol) were dissolved in dichloromethane (30 ml), 1,3,5-benzenetricarboxylic acid chloride (1 mmol) was added and stirred at room temperature for 12 h. After TLC detection of the reaction, the solvent was removed by vacuum distillation using a rotary evaporator. 50 mL of ethyl acetate was added, and the mixture was washed 3 times with an equal volume of saturated sodium chloride solution, dried over anhydrous sodium sulfate for 30 min, and the solvent was removed by vacuum distillation using a rotary evaporator. Column chromatography was used for separation and purification (eluent: methanol: dichloromethane volume ratio = 1:30), and compound L2 was obtained with a yield of 80%. 1 H NMR(400MHz,Chloroform-d)δ8.78(s,3H),8.72(s,3H),7.85(s,3H),4.60(s,3H),3.45–3.08(m,6H),3.03– 2.80(m,18H),1.93–1.64(m,21H),1.28(d,J=23.9Hz,96H),0.93(t,J=5.7Hz,18H),0.87(t,J=6.7Hz,18H).

[0074] Example 2

[0075] Synthesis of compound M2

[0076]

[0077] The synthesis of compound 5 was as described in the synthesis of compound 3 in Example 1, except that BOC-L-leucine was replaced by BOC-L-methionine; the other reaction conditions and steps were the same as in Example 1. The single-step yield of compound 5 was 71%, the single-step yield of compound 6 was 94%, and the single-step yield of compound M2 was 82%. 1 H NMR(400MHz,Chloroform-d)δ8.80(s,3H),8.45(s,3H),7.92(s,3H),4.70(d,J=10.4Hz,3H),3.38(d,J=27.1Hz,6H),2.98–2.80(m,18H),2.6 8–2.60(m,6H),2.25(td,J=14.6,13.9,7.7Hz,6H),2.11(s,9H),1.81( s,6H),1.68–1.65(m,6H),1.42–1.13(m,96H),0.87(t,J=6.7Hz,18H).

[0078] The methods of Example 1 and Example 2 can also be used to prepare compounds L1, L3, L4, M1, M3, and M4, which are not described in detail here. The hydrogen spectrum data of some compounds are shown in Table 2.

[0079] Table 2

[0080]

[0081]

[0082] Example 3

[0083] Preparation and characterization of lipid nanoparticles

[0084] The lipid compound M2, DOPE, cholesterol, and DMG-PEG prepared in Example 2 were dissolved in anhydrous ethanol at a molar ratio of 35:30:25:0.5 to prepare a lipid ethanol solution, wherein the concentration of the lipid compound M2 was 10 mg / ml. EGFP (or Luciferase) mRNA was dissolved in a citrate buffer (10-50 mM, pH = 4) to prepare an mRNA aqueous solution. The lipid ethanol solution and the mRNA aqueous solution were quickly mixed using a NanoAssemblr microfluidic device (Precision Nanosystem) to prepare a solution containing lipid nanoparticles. Among them, the lipid compound: mRNA weight ratio was 10:1. Subsequently, lipid nanoparticles encapsulating mRNA can be obtained by dialysis, ultrafiltration, and the like.

[0085] The morphology and physicochemical properties of the lipid nanoparticles were then further characterized. The morphology of the lipid nanoparticles was characterized using a transmission electron microscope, the nanosize, polydispersity index (PDI) and Zeta potential were characterized using a dynamic light scattering laser particle size analyzer (Malvern Zetasizer Nano ZS), and the encapsulation efficiency was determined using the Quant-iT RiboGreen RNAAssay Kit RNA quantitative detection kit.

[0086] The results are as follows Figure 1-3 As shown, the lipid nanoparticles are spherical, with a particle size within 200 nm, a surface charge close to neutrality, and a good encapsulation efficiency (>80%), indicating that lipid nanoparticles composed of ionizable lipids of benzamide, cholesterol, phospholipids and PEG lipids can effectively encapsulate mRNA.

[0087] In vitro transfection experiment of lipid nanoparticles

[0088] The prepared lipid compounds L1-L4 and M1-M4 were used to prepare lipid nanoparticle solutions containing EGFP mRNA according to Example 3 (the weight ratio of lipid compound: mRNA was 10:1), and were named LLNP1, LLNP2, LLNP3, LLNP4, MLNP1, MLNP2, MLNP3, and MLNP4, respectively.

[0089] RAW264.7 cells in the logarithmic growth phase were inoculated into a 96-well plate containing DMEM medium at a density of 1*10 per well. 5 cells, and prepared for transfection after the cells adhered (37°C, about 12 hours). Lipid nanoparticles containing 0.2 μg mRNA were added to each well, and 3 replicate wells were set up for each group. After 24 hours of transfection, the transfection efficiency of each group of cells was detected by flow cytometry, and the transfection efficiency of LLNP1-4 and MLNP1-4 was 53.64%, 78.99%, 62.64%, 51.51%, 59.99%, 85.38%, 68.04%, and 64.29%, respectively.

[0090] The transfection results were as follows Figure 5 As shown, the transfection effects of LNPs prepared by using ionizable benzamide lipids with different linked amino acids and tail chain lengths are different. Lipids containing methionine may interact with groups in RNA through hydrogen bonds through the methylthiol group, and can better deliver nucleic acid molecules.

[0091] Biocompatibility experiments of lipid nanoparticles

[0092] Cell viability was determined using CCK-8 (cell counting kit-8). RAW264.7 cells in the logarithmic growth phase were inoculated in a 96-well plate containing DMEM medium at a density of 1*10 per well. 5 cells and incubated in a cell culture incubator for 24 hours. Then the original cell culture medium was replaced with 100uL LNP (containing mRNA 20ug / mL) cell culture medium and incubated for 4 hours. Subsequently, the cell supernatant was removed, fresh cell culture medium was added, and incubation continued for 20 hours. Finally, the supernatant in the well plate was removed, 100μL of fresh cell culture medium containing CCK-8 working solution (10μL / mL) was added, and incubated for 2 hours. The cell viability of each group of LNPs was detected using a multifunctional microplate, and the viability of LLNP1-4 and MLNP1-4 were 96%, 98%, 95%, 94%, 97%, 96%, 96%, and 95%, respectively.

[0093] Cell viability (%) = [A1-A0] / [A2-A0] × 100; A1 is the absorbance of the drug-treated group, A0 is the absorbance of the blank group, and A2 is the absorbance of the control group. Cells not treated with LNP were used as the control group, and their cell viability was set as 100%.

[0094] The cell viability results showed that within the limited LNP concentration range, all groups of LNPs prepared with benzamide ionizable lipids showed no obvious cytotoxicity and had good biocompatibility.

[0095] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A benzamide ionizable lipid or a salt thereof, characterized in that: Its structural formula is shown in Formula I: Wherein, R0 is selected from L-type or D-type amino acid side chain groups; R1-R6 are each independently selected from substituted or unsubstituted C6-C 24 Alkyl; or, substituted or unsubstituted C6-C 24 or, substituted or unsubstituted C6-C 24 Alkynyl; R7 is selected from H, substituted or unsubstituted C1-C 10 alkyl; m is an integer selected from 1 to 8; X is selected from O or NH.

2. The benzamide ionizable lipid or its salt according to claim 1, characterized in that: The amino acid of the side chain group of R0 is selected from glycine, alanine, proline, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, asparagine, glutamine, lysine, histidine, arginine, aspartic acid or glutamic acid; Preferably, the amino acid of the side chain group of R0 is selected from glycine, alanine, proline, valine, leucine, isoleucine, methionine, lysine, histidine or arginine; More preferably, the amino acid of the side chain group of R0 is leucine or methionine.

3. The benzamide ionizable lipid or its salt according to claim 1, characterized in that: R1-R6 are each independently selected from substituted or unsubstituted C6-C 24 alkyl; Preferably, R1-R6 are each independently selected from C8-C 14 Straight chain alkyl; Or, R7 is H; X is NH; m is 4.

4. The benzamide ionizable lipid or its salt according to claim 1, characterized in that: The benzamide ionizable lipid is selected from one of the following compounds:

5. A nano delivery system, characterized in that: The invention comprises the benzamide ionizable lipid or its salt according to any one of claims 1 to 4.

6. The nano delivery system according to claim 5, characterized in that: Also include one or more of helper lipids, cholesterol and its derivatives or PEG lipids; Preferably, the helper lipid is a phospholipid or a derivative thereof; Further preferably, the auxiliary lipid is selected from one or more of distearoylphosphatidylcholine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine, diethyl pyrocarbonate, dilauroylphosphatidylcholine, phosphatidylcholine, egg yolk lecithin, hydrogenated soybean phosphatidylcholine, sphingomyelin or dimyristoylphosphatidylcholine; Preferably, the cholesterol derivative is selected from one or more of sterols and their derivatives, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatine, ursolic acid, α-tocopherol or corticosteroids; Preferably, the PEG lipid is selected from one or more of DSPE-PEG, DMG-PEG, DPPE-PEG or DMA-PEG.

7. The nano delivery system according to claim 5, characterized in that: It comprises the benzamide ionizable lipid or its salt, auxiliary lipid, cholesterol or its derivative or PEG lipid, wherein the molar ratio of the benzamide ionizable lipid or its salt, auxiliary lipid, cholesterol or its derivative and PEG lipid is 20-50:20-60:10-40:0.5-10.

8. Use of the nano delivery system according to any one of claims 1 to 7 in the preparation of nucleic acid drugs.

9. The use according to claim 8, characterized in that: The nucleic acid molecule in the nucleic acid drug is selected from one or more of small interfering RNA, messenger RNA, microRNA, circular mRNA, long non-coding RNA, plasmid DNA, mini circle DNA, antisense oligonucleotide, small activating RNA or nucleic acid aptamer; Preferably, the nucleic acid molecule is small interfering RNA, messenger RNA or circular mRNA.

10. The use according to claim 8, characterized in that: In the nucleic acid drug, the mass ratio of the benzamide ionizable lipid or its salt to the nucleic acid molecule is 1-100:1; Preferably, the particle size of the nucleic acid drug is 1-1000 nm; Preferably, the nucleic acid drug includes a targeting molecule, and the targeting molecule is located in the nucleic acid drug or on the surface of the nucleic acid drug; Preferably, the targeting molecule is selected from proteins, peptides, glycoproteins, lipids, small molecules or nucleic acids; Preferably, the nucleic acid drug is used for preventing and / or treating cancer, inflammation, fibrotic disease, autoimmune disease, infection, mental disorder, blood disease, chromosomal disease, genetic disease, connective tissue disease, digestive disease, ear, nose and throat disease, endocrine disease, eye disease, reproductive disease, heart disease, kidney disease, lung disease, metabolic disease, oral disease, musculoskeletal disease, neonatal screening, nutritional disease, parasitic disease or skin disease.

Citation Information

Patent Citations

  • Ionizable lipid, cationic lipopeptide, lipid nanoparticles and preparation method and application thereof

    CN117567309A

  • Cross-linked star-shaped self-assembled polypeptides and its use as carriers in biomedical applications

    US20180228911A1